


Supplementary material

Stereotactic or conformal radiotherapy for adrenal metastases – patient characteristics and outcomes in a multicenter analysis

Daniel Buergy (MD), Florian Würschmidt (MD), Eleni Gkika (MD), Juliane Hörner-Rieber (MD), Stefan Knippen (MD), Sabine Gerum (MD), Panagiotis Balermipas (MD), Christoph Henkenberens (MD), Theresa Voglhuber, Christine Kornhuber (PhD), Steffen Barczyk (MD), Barbara Röper (MD), Ali Rashid (MD), Oliver Blanck (PhD), Andrea Wittig (MD), Hans-Ulrich Herold (MD), Thomas B. Brunner (MD), Rainer J. Klement (PhD), Klaus Henning Kahl (MD), Ilja F. Ciernik (MD), Annette Ottinger (MD), Victor Izaguirre (MD), Florian Putz (MD), Laila König (MD), Michael Hoffmann (MD), Stephanie E. Combs (MD), Matthias Guckenberger (MD), Judit Boda-Heggemann (MD, PhD)


Table of contents

1. Supplementary figure 1
2. Supplementary figure 2
3. Supplementary figure 3
4. Supplementary figure 4




Suppl. Fig. 1. Freedom from local progression (FFLP) by treatment group.


This figure shows a Kaplan-Meier function with freedom from local progression (FFLP) as an endpoint. The curves show 3DCRT/IMRT, Pall-RT, and SBRT groups, respectively. After SBRT, FFLP was significantly higher compared to Pall-RT ($p = 0.026$). No statistically significant difference in FFLP was observed after 3DCRT/IMRT compared to SBRT or after 3DCRT/IMRT compared to Pall-RT (both $p > 0.05$).



Suppl. Fig. 2. Overall survival by treatment group (SBRT vs. pall-RT; $p = 0.041$)



Suppl. Fig. 3. Overall survival by treatment group (SBRT vs. 3DCRT/IMRT; $p = 0.0028$)



Suppl. Fig 4. Overall survival by treatment group (3DCRT/IMRT vs. pall-RT; no significant difference)